Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy

Резултати

Naziv:	Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy
Autori:	Mateos, Maria-Victoria; Szarejko, Monika; Bila, Jelena S. ; Schjesvold, Fredrik; Spicka, Ivan; Maisnar, Vladimir; Jurczyszyn, Artur; Grudeva-Popova, Zhanet; Hajek, Roman; Usenko, Hanna; Thuresson, Marcus; Norin, Stefan; Jarefors, Sara; Richardson, Paul; Pour, Ludek;
Godina:	2023
Publikacija:	Clinical lymphoma, myeloma & leukemia (The Abstract from International Myeloma Society 20th Annual Meeting and Exposition, 27-30 September 2023, Athens, Greece)
ISSN:	2152-2650 Clinical Lymphoma Myeloma and Leukemia Pretraži identifikator
Izdavač:	[New York] : Elsevier
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 23 br. Suppl 2 str. S200-S201
DOI:	10.1016/S2152-2650(23)01914-6
WoS-ID:	001079705400348
URI:	https://enauka.gov.rs/handle/123456789/934852
URL:	https://www.sciencedirect.com/science/article/abs/pii/S2152265023019146
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Алт метрика

Dimensions

Unpaywall

Google Scholar^TM

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.